26.97
-1.6(-5.60%)
Currency In USD
| Previous Close | 28.57 |
| Open | 27.44 |
| Day High | 28.15 |
| Day Low | 26.6 |
| 52-Week High | 31.77 |
| 52-Week Low | 11.86 |
| Volume | 2.05M |
| Average Volume | 1.62M |
| Market Cap | 3.3B |
| PE | -79.32 |
| EPS | -0.34 |
| Moving Average 50 Days | 27.34 |
| Moving Average 200 Days | 20.7 |
| Change | -1.6 |
If you invested $1000 in Arcutis Biotherapeutics, Inc. (ARQT) since IPO date, it would be worth $1,237.16 as of February 28, 2026 at a share price of $26.97. Whereas If you bought $1000 worth of Arcutis Biotherapeutics, Inc. (ARQT) shares 4 years ago, it would be worth $771.23 as of February 28, 2026 at a share price of $26.97.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Arcutis Management to Present at TD Cowen’s 46th Annual Health Care Conference
GlobeNewswire Inc.
3 hours ago
WESTLAKE VILLAGE, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis
Professional Golfer Max Homa Joins Arcutis’ Free to Be Me Campaign, Urging Individuals with Seborrheic Dermatitis to Tee Up a Conversation with Their Healthcare Provider About Long-Term Treatments
GlobeNewswire Inc.
Feb 24, 2026 2:15 PM GMT
Max Homa shares his journey with seborrheic dermatitis to encourage others to take control of their symptomsZORYVE® (roflumilast) foam 0.3% is a once-daily, steroid-free, leave-in topical foam uniquely formulated to treat the itching, redness, and fl
Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis
GlobeNewswire Inc.
Feb 02, 2026 1:00 PM GMT
58% of participants achieved a 75% improvement in Eczema Area and Severity Index (EASI-75) with ZORYVE cream 0.05% at Week 4Investigational ZORYVE cream 0.05% was well tolerated and demonstrated a safety profile consistent with previous studies, with